Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Saved in:
| Title: | Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression. |
|---|---|
| Authors: | Tantawy SI; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Internal Medicine Department, College of Medicine, Suez Canal University, Ismailia, Egypt., Aslan B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Manyam G; Department of Bioinformatics and Computer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Iles LR; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Timofeeva N; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Singh N; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thompson PA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Desikan SP; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gandhi V; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Oct 27; Vol. 15 (1), pp. 183. Date of Electronic Publication: 2025 Oct 27. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-025-01382-x |
